Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LGND by emailGet an email when LGND pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LGND, unsubscribe in one click. Privacy
📣 What LGND Says Is Next
by the end of the year · “Ligand earns a 9% royalty on net sales of Filspari Palvella announced positive Phase 3 data in MLM for its QTORIN rapamycin program and plans to file an NDA by the end of the year.”
Company press release, Apr 27, 2026 · SEC filing
mid-2027 · “The ongoing Phase 3 ELAINE-3 clinical trial is greater than 50% enrolled with data expected in mid-2027.”
Company press release, Feb 26, 2026 · SEC filing
second half of 2026 · “Palvella plans to initiate a Phase 2 trial evaluating Qtorin rapamycin for clinically significant angiokeratomas in the second half of 2026.”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LGND picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LGND and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.